Does Xenon Anesthesia Inhibit Cholinesterases?

Ishiguro, Yoshiki; Kikuchi, Tatsuya; Etsuki, Hiromi; Niimi, Yoshinari; Goto, Takahisa; Morita, Shigeho; Irie, Toshiaki

doi:10.1097/00000542-200303000-00034

Cited by 6 publications

(4 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The K m of 1-methylpiperidin-4-yl acetate, a secondary alcohol ester, is reported to be 2.4 mM. 9) This K m value is higher than the K m for MATP and suggests that the ester moiety fixed on the piperidine ring would be relatively hard to fit into the active site. Similarly, the slightly lower V max of MATPϩ compared with MATP would be due to structural differences.…”

Section: Discussionmentioning

confidence: 97%

Piperidine-4-methanthiol Ester Derivatives for a Selective Acetylcholinesterase Assay

Kikuchi

Okamura

Fukushi

et al. 2010

Biological & Pharmaceutical Bulletin

Self Cite

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 97%

Piperidine-4-methanthiol Ester Derivatives for a Selective Acetylcholinesterase Assay

Kikuchi

Okamura

Fukushi

et al. 2010

Biological & Pharmaceutical Bulletin

Self Cite

View full text Add to dashboard Cite

“…Furthermore, plasma cholinesterase, responsible for the metabolism of mivacurium 17 is not inhibited by either propofol or xenon. 18 No patient showed an unusual prolongation of recovery, suggesting pseudocholinesterase deficiency.…”

Section: Discussionmentioning

confidence: 97%

Xenon does not modify mivacurium induced neuromuscular block

Kunitz

Baumert

Hecker

et al. 2005

Can J Anesth/J Can Anesth

View full text Add to dashboard Cite

Purpose:The interaction between mivacurium and inhaled anesthetics is known, with the exception of xenon. We compared the pharmacodynamics of mivacurium during xenon anesthesia vs total iv anesthesia with propofol.Methods: This randomized controlled trial was carried out in the Aachen University Hospital. Forty-two adult patients ASA I or II, aged 18 to 60 yr, were randomized to receive either xenon or propofol anesthesia. Anesthesia was induced with propofol and remifentanil in both groups (each n = 21). The xenon group received xenon via facemask until an end-expiratory concentration of 60% was reached for one minute. Meanwhile, the acceleromyograph was calibrated and a train-of-four stimulation of the adductor pollicis muscle was started. After stabilization of the signal for five minutes, a single bolus of 0.16 mg·kg -1 mivacurium was injected. Anesthesia was maintained with xenon and remifentanil or with propofol and remifentanil.Results: There were no significant differences between groups with respect to onset time (xenon 180 ± 64 vs propofol 195 ± 77 sec; P = 0.39), duration (xenon 16.18 ± 4.97 vs propofol 15.68 ± 6.17 min; P = 0.73), recovery index (xenon 5.63 ± 2.48 vs propofol 5.73 ± 2.12 min; P = 0.42) and clinical recovery (xenon 8.75 ± 2.57 vs propofol 9.28 ± 2.28 min; P = 0.22). Conclusion:We conclude that the neuromuscular blocking effects of mivacurium are similar when given during propofol vs xenon anesthesia. (xénon 180 ± 64 vs propofol 195 ± 77 s ; P = 0,39), à sa durée (xénon 16,18 ± 4,97 vs propofol 15,68 ± 6,17 min ; P = 0,73), à l'indice de récupération (xénon 5,63 ± 2,48 vs propofol 5,73 ± 2,12 min ; P = 0,42) et à la récupération clinique (xénon 8,75 ± 2,57 vs propofol 9,28 ± 2,28 min ; P = 0,22). Objectif : L'interaction entre le mivacurium et les anesthésiques Résultats : Il n'y a pas eu de différence intergroupe significative quant au délai d'installation du bloc Conclusion : Les effets neuromusculaires bloquants du mivacurium sont similaires pendant l'anesthésie au propofol ou au xénon.T HE combination of a short-acting opioid and neuromuscular blocking drug, such as remifentanil and mivacurium, allow rapid emergence and recovery from anesthesia. 1 On the other hand, it is well known that most inhaled anesthetics variably prolong and enhance the effects of nondepolarizing neuromuscular blocking drugs, compared to total iv anesthesia. 2-4 Xenon, a rediscovered inhaled anesthetic with an extremely low blood-gas solubility of 0.115 to 0.14 5 and a minimum alveolar concentration (MAC) of 63 to 71%, 6,7 has proven its clinical safety and efficacy in the past. 8 With its ecological and pharmacological qualities, xenon is an interesting alternative to other inhaled anesthetics. The combination of a short-acting opioid, a short duration

show abstract

“…Furthermore, measurement of first-order rate would be suitable in the evaluation of the compound as a PET probe, since the value obtained from PET study is the first-order rate constant. In addition, this method was used for evaluation of the AChE inhibition effect of an anesthetic agent with [ 14 C]MP4A as a AChE specific regent in vitro [65].…”

Section: Methods Of Measuring Hydrolysis Ratementioning

confidence: 99%

Cerebral Acetylcholinesterase Imaging: Development of the Radioprobes

Kikuchi¹,

Okamura²,

Fukushi³

et al. 2007

CTMC

Self Cite

View full text Add to dashboard Cite

Cerebral acetylcholinesterase (AChE) imaging is not only useful for diagnosis of dementia disorders but also for therapeutic monitoring of the effects of cholinesterase (ChE) inhibitors and for decision of the appropriate clinical dosage of newly developed ChE inhibitors. Several ChE inhibitors or the derivatives such as 1,2,3,4-tetrahydro-9-methylaminoacridine (MTHA), donepezil, physostigmine, CP126,998 and 2-fluoro-CP118,954 have been labeled with positron emitters for mapping cerebral AChE by positron emission tomography (PET). When [(11)C]MTHA or [(11)C]donepezil was injected in animals, the uptake poorly reflect the regional distribution of AChE in the brain because of high non-specific binding and/or less specific to AChE in vivo in the brain tissue. [(11)C]physostigmine, [(11)C]CP126,998 and 2-[(18)F]fluoro-CP118,954 were distributed corresponding well to the regional AChE activity in animals, and also former two probes were successfully applied to clinical PET trial. The other approach is measuring cerebral AChE activity with radiolabeled acetylcholine analogue substrates. We have developed the principle for measuring cerebral enzyme activity by PET and radiolabeled N-methylpiperidinyl esters for quantitative measurement of cerebral AChE activity. N-[(11)C]methylipiperidin-4-yl acetate (MP4A) and N-[(11)C]methylpiperidin-4-yl propionate (MP4P) have been used for clinical studies of other demented disorders including Alzheimer's disease (AD), and the probes have demonstrated not only the reduction of AChE activity in the cerebral cortex of patients with AD but also the inhibitory effects of donepezil and rivastigmine on AChE activity in the brain of AD patients. Following this succession, widely available [(18)F]-labeled derivatives of MP4A and MP4P have been developed based on the structure-activity relationships between AChE and piperidinol esters.

show abstract

Does Xenon Anesthesia Inhibit Cholinesterases?

Cited by 6 publications

References 5 publications

Piperidine-4-methanthiol Ester Derivatives for a Selective Acetylcholinesterase Assay

Piperidine-4-methanthiol Ester Derivatives for a Selective Acetylcholinesterase Assay

Xenon does not modify mivacurium induced neuromuscular block

Cerebral Acetylcholinesterase Imaging: Development of the Radioprobes

Contact Info

Product

Resources

About